* Miromatrix Medical Inc MIRO.OQ MIRO.O is expected
to show a
fall in quarterly revenue when it reports results on November
14.
* The Eden Prairie Minnesota-based company is expected to
report
a 65.0% decrease in revenue to $3.5 thousand from $10 thousand a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Miromatrix Medical
Inc is
for a loss of 40 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Miromatrix
Medical Inc is $15, above its last closing price of $4.35.
This summary was machine generated November 11 at 23:10 GMT.
All figures in US dollars unless otherwise stated